INTRODUCTION {#S1}
============

The incidence of cardiovascular diseases (CVDs) has been increased in recent decades, it has been estimated that CVDs are the most common cause of death in Iran.[@B1],[@B2] As a result cardiovascular drugs has moved to the third place among all drug classes prescribed in the country. With introducing new cardiovascular drugs to the market, Pharmacotherapy of CVDs has improved rapidly during last few years. The problem of adverse drug events accompanied with different drug therapies has been reported since 1961. It has been reported that adverse drug events are considered as 4th to 6th cause of death in the US.[@B3] Studies show that cardiovascular drugs are among the most commonly cause of adverse events in hospitalized patients.[@B4] Some studies report that cardiovascular drugs may cause half of all hospital admissions due to adverse drug reactions.[@B5] Another study describes that 4% of adverse events induced by cardiovascular drugs are serious ADEs.[@B6] Almost 10% of all medication-related office visits result from cardiovascular drug reactions, and most of those visits are related to dermatological reactions.[@B7] In a literature review of ten studies published between 1994 and 2001, cardiovascular drugs were implicated for 17.9% of preventable adverse drug events.[@B8] There are several studies on hospitalized patients to detect the rate of adverse events induced by cardiovascular drugs but there are no studies on outpatients to the best of our knowledge. This is the first study evaluating adverse events following cardiovascular drugs use in outpatients.

METHODS {#S2}
=======

This cross-sectional study was conducted in the cardiovascular clinic of a 1000 bed tertiary teaching hospital in Tehran. All patients visited in the cardiovascular clinic during an eighth months period were evaluated for cardiovascular drugs induced adverse reactions. Patients previously used or newly started on cardiovascular drugs were monitored and followed for detecting and recording of ADRs. Adverse drug reactions were detected by daily interviewing patients, consulting with physicians and reviewing patient charts. The WHO definition for "adverse drug reaction" was used in this study: "Any noxious or unintended response to a drug, which occurs at doses normally used in human for prophylaxis, diagnosis or treatment of disease or for the modification of physiological function".[@B9]

If a sign or symptom suspected to be induced by cardiovascular drug was found, the national form for ADRs (yellow card) was filled. Patient demographics, pre-existing diseases and drug history were recorded. The time of onset and duration of the reaction, suspected drug, outcome and actions taken for managing the adverse reaction were precisely recorded. The ADRs were recorded based on WHO terminology.[@B10] Causality assessments were performed using WHO criteria.[@B11]

Seriousness of recorded ADRs were assessed based on WHO definition, which involves any ADRs resulted in death, life threatening situation, hospitalization, prolonged hospital stay, disability and birth defect.[@B12] Preventable adverse events were determined applying Schumock questionnaire.[@B13]

All patients entered the study were classified to two different groups: Patients who developed at least one ADR (ADR patients) and patients who never experienced an ADR (Non-ADR patients). These two groups of patients were compared in sex and age by using chi-square test. Also the duration of drug usage were compared in ADR and Non-ADR patients using t-test. For assessing the relationship between frequencies of ADRs occurred and the number of drugs used, Pearson analysis was performed.

RESULTS {#S3}
=======

A total of 518 patients, 212 men and 306 women, using cardiovascular medications entered the study. One hundred and five patients (20.3%) including 34 men and 71 women experienced at least one ADR. There were 54 patients (51.4%) who developed more than one ADR. Two ADRs in 26 patients (24.8%), three ADRs in 21 (20%), four ADRs in 5 (4.8%), five ADRs in 1 (1%) and six ADRs in 1 (1%) patient was reported. Detected ADRs were mostly observed in the age group of 51-60 ([Table 1](#T1){ref-type="table"}). Calcium channel blockers and potassium sparing diuretics had the highest and lowest rate of ADRs respectively ([Table 2](#T2){ref-type="table"}). The highest rate of ADRs was recorded to be induced by Diltiazem (23.5%) and the lowest rate was related to Atenolol (3%). Central nervous system and Gastrointestinal system disorders were the most frequent system-organ classes affected with ADRs. ([Table 3](#T3){ref-type="table"}) Headache, vertigo, weakness, nausea and vomiting were the most frequent reactions. ([Table 4](#T4){ref-type="table"}) Among ADRs evaluated, 1.1% was recognized as serious and 1.9% as preventable ADRs. Causality assessment of ADRs revealed that the most frequent ADRs (75.9%) were recognized to be certain, followed by 19.2% as possible, 3% as probable and 1.9% as unlikely. Withdrawal of suspected drug was necessary in 22.2% of ADR patients, the treatment was continued in 65.6%, the dosage was decreased in 6.3%, the treatment was continued by alternate drug in 3.7% and 2.2% of the patients went through symptomatic therapy. The most common outcome of ADRs was "not yet recovered", which refers to the ADRs not completely recovered by the end of the study ([Table 5](#T5){ref-type="table"}).

###### 

Number of ADRs in different age groups.

  ------- ------------------------ --------------------------- ------------
  Age     Patients with ADRs (%)   Patients without ADRs (%)   Total (%)
  ≤10     0                        2 (100%)                    2 (100%)
  11-20   0                        18 (100%)                   18 (100%)
  21-30   5 (11.4%)                39 (88.6%)                  44 (100%)
  31-40   9 (13.8%)                56 (86.2%)                  65 (100%)
  41-50   26 (26.0%)               74 (74.0%)                  100 (100%)
  51-60   37 (27.6%)               97 (72.4%)                  134 (100%)
  ≥61     28 (18.1%)               127 (81.9%)                 155 (100%)
  Total   105 (20.3%)              413 (79.7%)                 518 (100%)
  ------- ------------------------ --------------------------- ------------

###### 

Number of ADRs induced by different subclasses of cardiovascular agents.

  ------------------------------------------- ------------------------ --------------------------- -------------
  Pharmacologic classification                Patients with ADRs (%)   Patients without ADRs (%)   Total (%)
  Angiotensin converting enzymes Inhibitors   40 (21.1%)               150 (78.9%)                 190 (100%)
  Calcium channel blockers                    24 (27.3%)               64 (72.7%)                  88 (100%)
  Beta -- blockers                            18 (5.2%)                330 (94.8%)                 348 (100%)
  Nitrates                                    37 (11.6%)               283 (88.4%)                 320 (100%)
  Loop diuretics                              15 (19.5%)               62 (80.5%)                  77 (100%)
  Thiazide diuretics                          1 (16.7%)                5 (83.3%)                   6 (100%)
  Potassium sparing diuretics                 2 (2.3%)                 86 (97.7%)                  88 (100%)
  Carbonic anhydrase inhibitors               0                        2 (100%)                    2 (100%)
  Alpha -- blockers                           3 (37.5%)                5 (62.5%)                   8 (100%)
  Peripheral vasodilators                     1 (100%)                 0                           1 (100%)
  Centrally -- acting antiadrenergics         1 (7.1%)                 13 (92.2%)                  14 (100%)
  Pyrimidine analogues                        2 (16.7%)                10 (83.3%)                  12 (100%)
  Benzofuran derivatives                      1 (20.0%)                4 (80.0%)                   5 (100%)
  Cardiac glycosides                          17 (14.9%)               97 (85.1%)                  114 (100%)
  Cinchona alkaloids                          0                        1 (100%)                    1 (100%)
  Sodium channel antagonists                  0                        1 (100%)                    1 (100%)
  Total                                       162 (12.7%)              1113 (87.3%)                1275 (100%)
  ------------------------------------------- ------------------------ --------------------------- -------------

###### 

Different system-organ classes affected by ADRs.

  -------------------------------------- ----------- ---------
  System-Organ Class                     Frequency   Percent
  Central Nervous System Disorders       134         49.6%
  Gastrointestinal System Disorders      61          22.6%
  Respiratory System Disorders           32          11.9%
  Cardiovascular System Disorders        28          10.4%
  Others                                 7           2.6%
  Skin and Appendages System Disorders   4           1.5%
  Genito-Urinary System Disorders        3           1.1%
  Hematologic Disorders                  1           0.4%
  Total                                  270         100%
  -------------------------------------- ----------- ---------

###### 

Different ADRs induced by cardiovascular agents.

  ---------------------- ----------- ------------------------------------
  Adverse Reaction       Frequency   \% of the reaction in ADR Patients
  Headache               62          59.0
  Vertigo                37          35.2
  Weakness               25          23.8
  Nausea                 23          21.9
  Cough                  20          19.0
  Mouth dry              15          14.2
  Hypotension            14          13.3
  Constipation           11          10.4
  Dyspnea                11          10.4
  Vomiting               10          9.52
  Dizziness              5           4.7
  Edema                  4           3.8
  Chest pain             4           3.8
  Pruritus               3           2.85
  Nightmare              3           2.85
  Paraesthesia           2           1.9
  Erratic Blood sugar    2           1.9
  Palpitation            2           1.9
  Tingling               2           1.9
  PVC                    2           1.9
  Throat itching         1           0.95
  Hematuria              1           0.95
  Insomnia               1           0.95
  Polyuria               1           0.95
  Epigastric pain        1           0.95
  Micturation            1           0.95
  Diarrhea               1           0.95
  Hirsutism              1           0.95
  Extremities coldness   1           0.95
  Leg pain               1           0.95
  Pancytopenia           1           0.95
  ST inversion           1           0.95
  AF rhythm              1           0.95
  Total                  270         100
  ---------------------- ----------- ------------------------------------

###### 

Outcome of detected ADRs induced by cardiovascular agents.

  ------------------- ----------- ---------
  Outcome             Frequency   Percent
  Unknown             77          28.5%
  Recovered           79          29.3%
  Not yet recovered   113         41.9%
  Hospitalization     1           0.4%
  Total               270         100%
  ------------------- ----------- ---------

The result of chi-squared test for comparing sex between ADR and Non-ADR patients showed that women significantly developed more ADRs in this study (chi square = 3.978, P\<0.05). Also the result of the chi-squared test for comparing the age groups between two groups of patients was significant, it appears that ADRs more frequently occurred with increasing age in this study (chi square = 15.871, P\<0.05). Conducting t-test for comparing duration of drug usage between ADR and Non-ADR patients implicated that there is a significant relationship between two groups. It appears that the average duration of drug usage is longer in Non-ADR group (t=-2.812, P\<0.05). The result of Pearson test implicated that there is a significant relationship between frequencies of ADRs occurred and the number of drugs used. It appears that with increasing the number of drugs used, the frequency of ADRs will increase (Pearson=0.259, P\<0.05).

DISCUSSION {#S4}
==========

In this study 105 patients (20.3%) developed at least one ADR. This rate is higher than the rate of 15.3% previously reported in a similar study conducted in Denmark.[@B14] This difference may be due to the difference between the population studied, types and number of drugs used by patients, definition used for ADR and the susceptibility of patients for developing adverse reactions induced by cardiovascular drugs. Most ADR patients in this study were in the age group of 51-60. This is partly in accordance with the result of a previous study conducted in Iranian hospitalized patients in two internal medicine wards in the same hospital.[@B15] There is a controversy in the literature on the relationship between age and developing ADRs.[@B16] Some studies have shown that ADRs may increase with increasing age; this could be due to polypharmacy used in old patients. Considering the result of chi-square test for analytical evaluation of the influence of age on occurring ADRs, it appears that older patients are more likely to experience an ADR. Gender difference in patients with or without ADRs has been described earlier[@B17], our findings support the theory of increased number of ADRs in women.

Calcium channel blockers especially Diltiazem had the highest rate of ADRs in our study. The results of a study conducted in a university hospital showed that Nitrates, Digoxin, Propranolol, Heparin, Warfarin, Anti-hypertensive and Anti-arrhythmic drugs together produced 48.5% of ADEs. In the study performed by Mjorndal et al.[@B18] in a clinic of internal medicine at a Swedish university hospital, cardiovascular drugs were the most common class of drugs involved in the induction of ADRs constituting 36.3% of the drugs associated with ADRs. The most offending cardiovascular drugs in that study were Metoprolol, Enalapril, Digoxin, Flodipine and Furosemide. Also in Danish trial[@B14], Diuretics, Beta-blockers and Calcium antagonists were responsible for 80% of all ADRs detected. Our study identified Central Nervous and Gastrointestinal System as the most frequent affected system-organ classes by ADRs, in which headache, vertigo, weakness, nausea and vomiting were the most reactions observed. This profile of adverse reactions is well adjusted with the pharmacological actions of most frequent suspected drugs for ADRs in this study, where as in other study conducted in Denmark hypokalemia was the most frequent ADR related to Thiazides.

Comparing our results with those in the literature, the percentage of preventable ADRs in this study (1.9%) is rather lower than those detected in other studies.[@B19] This may be partly due to different drug classes studied in different trials, e.g. in the similar study designed in two internal medicine wards 58.8% of detected ADRs were reported to be preventable based on the same questionnaire.[@B15] Also in a literature review conducted on ten studies published between 1994 and 2001, cardiovascular drugs were implicated for 17.9% of preventable adverse drug events.[@B8]

This study showed that the average duration of drug usage is longer in Non-ADR group. Also it appears that most detected ADRs have been occurred shortly after starting cardiovascular drugs and incidence of ADRs are not related to the duration of usage. Like many other studies, increasing the number of drugs led to increased frequency of ADRs.

CONCLUSIONS {#S5}
===========

Monitoring adverse drug reactions in patients using cardiovascular drugs is a matter of importance since this class of medicine is usually used by elderly patients with critical conditions and underlying diseases. The frequency of ADRs occurrence can be reduced by decreasing the number of drugs prescribed. ADRs of Cardiovascular drugs mostly occur in first days of treatment, therefore monitoring patients in first days of using cardiovascular drugs could help in preventing ADRs. To determine the rate and nature of adverse events induced by different subclasses of cardiovascular drugs, more studies are recommended in various populations.
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